Programmed Cell Death Ligand-1 Blockade in Urothelial Bladder Cancer: To Select or Not to Select
- 10 September 2016
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (26), 3115-3116
- https://doi.org/10.1200/jco.2016.68.4696
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialThe Lancet, 2016
- New Strategies in Bladder Cancer: A Second Coming for ImmunotherapyClinical Cancer Research, 2016
- Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung CancerJAMA Oncology, 2016
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell CarcinomaCancer Immunology Research, 2015
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Chemotherapy for Bladder Cancer: Treatment Guidelines for Neoadjuvant Chemotherapy, Bladder Preservation, Adjuvant Chemotherapy, and Metastatic CancerUrology, 2007